Sharing Corporate and Shareholder Value through Restricted Stock Compensation
First written in FY2019. 16 of 20 entries say "Advanced", first in FY2020. Latest entry: 2026-08-18.
- FY2026AdvancedAnnual report
「Other (exercise of stock acquisition rights): 348,800 shares, ¥41,979,123 / Other (disposal of treasury shares under the restricted stock compensation plan): 76,932 shares, ¥9,258,993」
Stock options representing 348,800 shares were exercised, and 76,932 treasury shares were disposed of under the restricted stock compensation plan, advancing the operation of the share-based compensation plans. - FY2026-H1AdvancedAnnual report
「The stock acquisition rights issued during the interim accounting period were as follows. Nomura Micro Science Co., Ltd. Eighth Series Stock Acquisition Rights Class and number of grantees: 6 executive officers of the company other than those concurrently serving as directors; 381 employees of the company Number of stock acquisition rights (units): 4,175 Class, details and number of shares underlying the stock acquisition rights: common shares, 417,500 Exercise period for the stock acquisition rights: from 24 September 2027 to 24 September 2032」
The company issued 4,175 eighth-series stock acquisition rights representing 417,500 common shares to 6 executive officers and 381 employees. An exercise period from 24 September 2027 to 24 September 2032 was established, further advancing the operation of the share-based compensation plan. - FY2025AdvancedAnnual report
「Other (exercise of stock acquisition rights): 292,800 shares, ¥35,225,912 / Other (disposal of treasury shares under the restricted stock compensation plan): 55,914 shares, ¥6,724,743」
Stock options representing 292,800 shares were exercised, and 55,914 treasury shares were disposed of under the restricted stock compensation plan, advancing the operation of the share-based compensation plans. - FY2025-H1AdvancedAnnual report
「At a meeting of the Board of Directors held on 15 October 2024, the company resolved to issue stock acquisition rights as stock options to its executive officers other than those concurrently serving as directors and to its employees.」
The company resolved to issue stock acquisition rights for executive officers and employees, capped at 449,200 common shares. The exercise period is from 24 November 2026 to 20 November 2031, further advancing the operation of the share-based compensation plan. - FY2024Restricted stock compensation limit expanded to ¥250 million annuallyAnnual report
「At the 55th Annual General Meeting of Shareholders held on 25 June 2024, a resolution was passed approving annual monetary compensation claims of up to ¥250 million, excluding the employee salary component for directors concurrently serving as employees, and an annual limit of 50,000 shares, for the grant of restricted stock to directors other than outside directors and directors who serve as Audit and Supervisory Committee members.」
The limit for restricted stock compensation for directors was expanded from up to ¥70 million annually to up to ¥250 million annually. In the fiscal year ended March 2024, 21,100 treasury shares were also disposed of. - FY2024-Q2AdvancedAnnual report
「Nomura Micro Science Co., Ltd. Sixth Series Stock Acquisition Rights Executive officers of the company other than those concurrently serving as directors: 7 Employees of the company: 129 Number of stock acquisition rights (units): 1,755 Common shares: 175,500 Exercise period for the stock acquisition rights From 22 September 2025 to 20 September 2030」
For the sixth-series stock acquisition rights, 1,755 rights representing 175,500 common shares were issued to 7 executive officers and 129 employees. An exercise period from 22 September 2025 to 20 September 2030 was established, further advancing the operation of the share-based compensation plan. - FY2024-Q1AdvancedAnnual report
「At a meeting of the Board of Directors held on 10 August 2023, the company resolved to issue stock acquisition rights as stock options to its executive officers other than those concurrently serving as directors and to its employees. The number of underlying shares is capped at 191,000 common shares, and the exercise period for the stock acquisition rights is from 22 September 2025 to 20 September 2030.」
The company resolved to issue new stock options for executive officers and employees, capped at 191,000 common shares. The purpose is to encourage contributions to long-term corporate value enhancement through alignment with performance and share value, further advancing the operation of the existing plan. - FY2023AdvancedAnnual report
「Other (exercise of stock acquisition rights): 77,000 shares, ¥36,970,643. Other (disposal of treasury shares under the restricted stock compensation plan): 21,000 shares, ¥10,081,912」
Stock options representing 77,000 shares were exercised, and 21,000 treasury shares were disposed of under the restricted stock compensation plan, advancing the operation of the share-based compensation plans. - FY2023-Q2AdvancedAnnual report
「The stock acquisition rights issued during the second quarter accounting period were as follows. Nomura Micro Science Co., Ltd. Fifth Series Stock Acquisition Rights: 106 employees; 1,875 stock acquisition rights; 187,500 common shares; exercise period from 23 September 2024 to 21 September 2029.」
For the fifth-series stock acquisition rights, 1,875 rights representing 187,500 common shares were issued to 106 employees, moving the plan from the resolution stage to the issuance and implementation stage. - FY2023-Q1AdvancedAnnual report
「At a meeting of the Board of Directors held on 10 August 2022, the company resolved to issue stock acquisition rights as stock options to its executive officers other than those concurrently serving as directors, directors and employees. The number of underlying common shares is capped at 188,500. 23 September 2024 to 21 September 2029」
The company resolved to issue stock acquisition rights as stock options for executive officers, directors and employees, capped at 188,500 common shares, with an exercise period from 23 September 2024 to 21 September 2029. - FY2022Share-based compensation limit expandedAnnual report
「Separately from the above compensation limit, at the 53rd Annual General Meeting of Shareholders held on 23 June 2022, a resolution was passed approving annual monetary compensation claims of up to ¥70 million, excluding the employee salary component for directors concurrently serving as employees, and an annual limit of 50,000 shares, for the grant of restricted stock to directors other than outside directors and directors who serve as Audit and Supervisory Committee members.」
The limit for restricted stock compensation was expanded from up to ¥30 million annually to up to ¥70 million annually and 50,000 shares annually. During the current fiscal year, 12,900 treasury shares were also disposed of. - FY2022-Q2AdvancedAnnual report
「The stock acquisition rights issued during the second quarter accounting period were as follows. Number of stock acquisition rights (units): 363 (Note 1). Class, details and number of shares underlying the stock acquisition rights (shares): common shares, 36,300 (Note 1). Exercise period for the stock acquisition rights: from 18 September 2023 to 14 September 2028.」
The company issued 363 fourth-series stock acquisition rights representing 36,300 common shares to 93 employees, advancing the operation of its existing share-based compensation and stock option plans. - FY2021AdvancedAnnual report
「Other (disposal of treasury shares under the restricted stock compensation plan): 15,800 shares, ¥7,578,423」
Under the restricted stock compensation plan, 15,800 treasury shares were disposed of during the current fiscal year, continuing the operation of the value-sharing plan with shareholders. - FY2021-Q2AdvancedAnnual report
「The stock acquisition rights issued during the second quarter accounting period were as follows. Number of stock acquisition rights (units): 1,635. Class, details and number of shares underlying the stock acquisition rights (shares): common shares, 163,500. Exercise period for the stock acquisition rights: from 20 September 2022 to 16 September 2027.」
For the stock options approved in the previous quarter, 1,635 stock acquisition rights representing 163,500 common shares were issued to 9 directors and 104 employees, moving the plan from the resolution stage to the issuance and implementation stage. - FY2021-Q1Stock option plan addedAnnual report
「At a meeting of the Board of Directors held on 11 August 2020, the company resolved to issue stock acquisition rights as stock options to its directors other than directors who serve as Audit and Supervisory Committee members and to its employees. Exercise period for the stock acquisition rights 20 September 2022 to 16 September 2027」
In addition to the existing restricted stock compensation plan, the company resolved to issue stock options for directors and employees. The number of underlying shares was capped at 164,000, with an exercise period from 20 September 2022 to 16 September 2027. - FY2020AdvancedAnnual report
「Other (disposal of treasury shares under the restricted stock compensation plan): 49,700 shares, ¥23,831,941」
Under the restricted stock compensation plan, 49,700 treasury shares were disposed of for directors, and the plan moved into the implementation stage. - FY2019First statedAnnual report
「At the 50th Annual General Meeting of Shareholders held on 20 June 2019, a resolution was passed approving annual monetary compensation claims of up to ¥30 million for the grant of restricted stock to directors other than outside directors and directors who serve as Audit and Supervisory Committee members, with the aim of providing incentives to enhance corporate value and further sharing value between directors and shareholders.」
The company disclosed a resolution to introduce a restricted stock compensation plan of up to ¥30 million annually, aimed at sharing value between directors and shareholders and enhancing corporate value.